
Discover the Unique Charm of Apellis’ Pegcetacoplan: A Standout Biotech Asset According to J.P. Morgan Analyst
Last Week’s Surprising Earnings Report from Apellis Pharmaceuticals: A Closer Look Last week, Apellis Pharmaceuticals Inc (APLS) sent shockwaves through the biotech industry with an earnings report that defied expectations. The company reported a loss of 29 cents per share for the fourth quarter, which was significantly better than the consensus loss of 37 cents….